$RIGL News Article - Rigel Announces Availability of REZLIDHIA(TM) (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
https://marketwirenews.com/news-releases/rige...65847.html